Lung Nodule Imaging Biobank for Radiomics and AI Research
NCT ID: NCT04270799
Last Updated: 2021-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2020-06-01
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
NCT07059923
AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer
NCT05375591
Advancing Lung Cancer Screening: Artificial Intelligence, Multimodal Imaging and Cutting-Edge Technologies for Early Detection and Characterization
NCT06531343
Integrating Artificial Intelligence Into Lung Cancer Screening.
NCT05704920
AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs
NCT06320184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung Nodules
A cohort of 1000 patients with incidental lung nodules will be identified using clinical records at participating NHS sites.
Link-anonymised CT scan images and data will be stored using a central database for radiomics and artificial intelligence research, to predict the risk of malignancy.
Machine Learning Classification
Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Machine Learning Classification
Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Baseline CT thorax imaging reported as having pulmonary nodule(s) between 5 and 30mm in the last 10 years.
* Ground truth known (either scan data showing stability for 2 years (based on diameter) or one year (based on volumetry), complete resolution, or biopsy-proven malignancy.
* Slice thickness \< 2.5mm.
Exclusion Criteria
* Slice thickness \> 2.5mm.
* Imaging \> 10 years old.
* Ground truth unknown.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RM Partners West London Cancer Alliance
UNKNOWN
Royal Brompton & Harefield NHS Foundation Trust
OTHER
University College London Hospitals
OTHER
Imperial College Healthcare NHS Trust
OTHER
Lewisham and Greenwich NHS Trust
OTHER_GOV
King's College Hospital NHS Trust
OTHER
Epsom and St Helier University Hospitals NHS Trust
OTHER
Institute of Cancer Research, United Kingdom
OTHER
Guy's and St Thomas' NHS Foundation Trust
OTHER
UCLH Biomedical Research Centre
UNKNOWN
Royal Marsden NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard Lee, MBBS PhD
Role: STUDY_CHAIR
The Royal Marsden Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Marsden - Surrey
Sutton, England, United Kingdom
Lewisham and Greenwich NHS Trust
London, Greater London, United Kingdom
Epsom and St Helier's Hospitals NHS Trust
Carshalton, Surrey, United Kingdom
University College London Hospitals NHS Foundation Trust
London, , United Kingdom
The Royal Brompton NHS Foundation Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCR5215
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.